{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:51:38Z","timestamp":1791363098897,"version":"4.3.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017218","name":"Giresun University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017218","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.exer.2026.111203","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T11:34:23Z","timestamp":1786880063000},"page":"111203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prophylactic fingolimod administration prevents the development of proliferative vitreoretinopathy in an experimental rat model"],"prefix":"10.1016","volume":"272","author":[{"given":"\u015eevval","family":"Efe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5166-6801","authenticated-orcid":false,"given":"Serkan","family":"\u00d6zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z\u00fcleyha","family":"Eri\u015fgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif","family":"Keskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130smail","family":"T\u00fcrko\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan Serdar","family":"Mutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2026.111203_bib1","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.exer.2026.111203_bib2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4103\/0976-500X.119726","article-title":"How to calculate sample size in animal studies?","volume":"4","author":"Charan","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"key":"10.1016\/j.exer.2026.111203_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.exer.2013.07.009","article-title":"The retinal pigment epithelium: an important player of retinal disorders and regeneration","volume":"123","author":"Chiba","year":"2014","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2026.111203_bib4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ana.22426","article-title":"Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis","volume":"69","author":"Cohen","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.exer.2026.111203_bib5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0002-9394(14)77370-2","article-title":"The role of cellular proliferation in an experimental model of massive periretinal proliferation","volume":"93","author":"Fastenberg","year":"1982","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2026.111203_bib6","first-page":"12","article-title":"Rhegmatogenous retinal detachment--an ophthalmologic emergency","volume":"111","author":"Feltgen","year":"2014","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.exer.2026.111203_bib7","first-page":"2157","article-title":"A new model of proliferative vitreoretinopathy","volume":"39","author":"Frenzel","year":"1998","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2026.111203_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.718902","article-title":"Fingolimod and diabetic retinopathy: a drug repurposing study","volume":"12","author":"Gesualdo","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.exer.2026.111203_bib9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1212\/WNL.0b013e318248deea","article-title":"Fingolimod-associated macular edema: incidence, detection, and management","volume":"78","author":"Jain","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.exer.2026.111203_bib10","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/BF00231411","article-title":"Postoperative retinal fibrosis\u2014a controlled clinical study of systemic steroid therapy","volume":"219","author":"Koerner","year":"1982","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.exer.2026.111203_bib11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/eye.2016.258","article-title":"Fingolimod: therapeutic mechanisms and ocular adverse effects","volume":"31","author":"Mandal","year":"2017","journal-title":"Eye (Lond.)"},{"key":"10.1016\/j.exer.2026.111203_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/815937","article-title":"Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside","volume":"2012","author":"Moysidis","year":"2012","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.exer.2026.111203_bib13","doi-asserted-by":"crossref","first-page":"9700","DOI":"10.1038\/s41598-024-60540-6","article-title":"Sphingosine-1-phosphate receptor 1\/5 selective agonist alleviates ocular vascular pathologies","volume":"14","author":"Nakamura","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.exer.2026.111203_bib14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10792-016-0318-0","article-title":"Histopathological and ophthalmoscopic evaluation of apocynin on experimental proliferative vitreoretinopathy in rabbit eyes","volume":"37","author":"Ozer","year":"2017","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.exer.2026.111203_bib15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1350-9462(01)00023-4","article-title":"Proliferative vitreoretinopathy: risk factors and pathobiology","volume":"21","author":"Pastor","year":"2002","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.exer.2026.111203_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.preteyeres.2015.07.005","article-title":"Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences","volume":"51","author":"Pastor","year":"2016","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.exer.2026.111203_bib17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.preteyeres.2013.12.006","article-title":"Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy?","volume":"40","author":"Pennock","year":"2014","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.exer.2026.111203_bib18","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.3390\/ijms19123885","article-title":"Characterizing sphingosine kinases and sphingosine 1-phosphate receptors in the mammalian eye and retina","volume":"19","author":"Porter","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.exer.2026.111203_bib19","first-page":"1325","article-title":"Proliferative vitreoretinopathy: current and emerging treatments","volume":"6","author":"Sadaka","year":"2012","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.exer.2026.111203_bib20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.exer.2008.07.005","article-title":"Sphingosine-1-phosphate (S1P) is a novel fibrotic mediator in the eye","volume":"87","author":"Swaney","year":"2008","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2026.111203_bib21","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.juro.2013.10.072","article-title":"Treatment with the immunomodulator FTY720 (fingolimod) significantly reduces renal inflammation in murine unilateral ureteral obstruction","volume":"191","author":"Thangada","year":"2014","journal-title":"J. Urol."},{"key":"10.1016\/j.exer.2026.111203_bib22","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0002-9394(98)00115-9","article-title":"Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial","volume":"126","author":"Wiedemann","year":"1998","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2026.111203_bib23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/jcp.21588","article-title":"Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization","volume":"218","author":"Xie","year":"2009","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.exer.2026.111203_bib24","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.devcel.2020.01.016","article-title":"S1PR1 signaling establishes AP-1 gradients for retinal endothelial cell specialization","volume":"52","author":"Yanagida","year":"2020","journal-title":"Dev. Cell"},{"key":"10.1016\/j.exer.2026.111203_bib25","first-page":"448","article-title":"Intravitreal methotrexate for the treatment of proliferative vitreoretinopathy","volume":"5","author":"Young","year":"2021","journal-title":"J. Vitreoretin. Dis."},{"key":"10.1016\/j.exer.2026.111203_bib26","first-page":"1591","article-title":"A rat model of proliferative vitreoretinopathy induced by RPE-J cells and platelet-rich plasma","volume":"248","author":"Zheng","year":"2010","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483526003593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483526003593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:08:49Z","timestamp":1791360529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483526003593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":26,"alternative-id":["S0014483526003593"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2026.111203","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylactic fingolimod administration prevents the development of proliferative vitreoretinopathy in an experimental rat model","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2026.111203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111203"}}